Plaque Psoriasis

Withdrawal and reinitiation of treatment with most biologic agents had minimal impact on efficacy in plaque psoriasis, according to a study.

Long-term treatment with tapinarof cream 1% was well tolerated and effective in continuing plaque psoriasis improvement, according to an extension study presented at the EADV Congress virtual meeting.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses what it means to patients to be diagnosed with psoriasis.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses the impact of the COVID-19 pandemic on psoriasis care.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses the future of psoriasis research.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses where topical therapies fit into the psoriasis treatment landscape.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses the current treatment options for psoriasis.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses how various psoriasis therapies should be positioned for personalizing patient care.

Secukinumab 300 mg administered with an auto-injector pen showed significant efficacy and tolerability compared with placebo, according to clinical trial results presented at the EADV Congress virtual meeting.

Skyrizi is now available as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis in the United States, AbbVie announced in a press release.